divis
beat cent rais estim
adjust ep dec vs last year cent figur oper
margin bp model lower-than-anticip adjust tax rate
ep estim previous compani rais guidanc
aid out-performance strong organ growth
ep estim estim
leader infect prevent equip report dec adjust ep vs
year earlier compar report year-over-year period yoy unless otherwis indic cent
figur adjust ep exclud purchas inventori step-up cost intang amort acquisition-
relat integr expens tax benefit due new tax law report net incom million
per share vs loss million cent per share
revenu increas million price ad bp constant currenc organ growth
vs last quarter revenu corpor total fell million intern
revenu less million revenu increas million
adjust gross profit rose million adjust gross margin increas bp
sale aid divest busi contribut bp favor mix price product
improv partial off-set neg fx adjust sg expens million equal
revenu vs expens million vs million equal revenu vs
adjust oper profit rose yoy million oper margin increas bp
yoy adjust tax rate around vs last year project adjust
net incom increas million net margin rose sale vs adjust ep
healthcar product sale infect prevent procedur solut
healthcar provid world-wide includ capit equip washer steam ga steril surgic
pleas see import disclosur end report
tabl light clean chemistri relat mainten instal servic well consum
flat flat organ constant currenc basi million capit equip fell shipment
time backlog increas yoy million consum increas servic increas
approxim busi replac remain project consum track
procedur volum equip align building/rehab project oper profit declin
million group margin vs impact flat revenu lower
healthcar specialti servic rang specialti servic healthcar provid includ
hospit steril servic instrument scope repair linen manag due linen
divestitur divest synergi netherland linen busi howev sale rose
organ constant currenc basi due mainli strength instrument manag servic im
north america ad im busi europ oper profit jump million
vs million group margin vs higher volum without addit growth
invest product improv remain commit im given strateg fit
appli steril technolog ast contract steril laboratori servic medic
devic manufactur pharmaceut custom other million sale rose
organ due increas volum segment core medic devic custom market share gain
group oper profit million group oper margin revenu vs
due revenu growth fx reorgan busi segment shift multi-year
contract sterilmed/johnson johnson million annual revenu segment
reorgan expect neg impact segment top bottom line bp similar
result current quarter held back million reduct oper incom
ast facil puerto rico produc million annual revenu impact hurrican impact
origin estim million facil back on-line much sooner anticip
life scienc ls consist capit equip consum product washer steril
etc equip mainten specialti servic pharmaceut manufactur research
institut lumpi busi due variabl construct deliveri schedul rose increas
organ million capit equip jump consum grew servic
increas ls backlog jump million new product includ hydrogen peroxid steril
well receiv ls longer lead time ls oper profit rose million
group margin slip vs due mix consum highest margin follow
servic capit equip
balanc sheet decemb includ cash equival million major held
outsid unit sate plan repatri million equiti billion debt billion
provid debt-to-tot capit ratio vs ebitda target near end
absent addit acquisit
flow oper cfo quarter million vs million year earlier total
debt reduc activ pursu acquisit primarili tuck-in share repurchas use
off-set option dilut compani rais dividend cent august quarterli rate
cent per share consecut annual increas
pleas see import disclosur end report
divis wellington shield co llc
plc
sale earn outlook
hospit spend remain solid-to-slightli north america europ remain strong asia-pacif
flatten strong growth previou year better growth expect given current
pipelin middl east pick disast last month latin america
seemingli bottom healthcar product benefit new product launch includ new
minut previous state-of-the-art biolog indic low temperatur steril name celer
one around new product includ equip consum ast open
facil ls strong perform continu aid market growth record
backlog new product
result could begin benefit capit equip order ship although face tough prior-year
comparison shipment rose difficult prior-year comparison ep
ep estim vs last year previou revenu
ep estim vs adjust record compani rais guidanc
previou project revenu flat billion
benefit favor fx around million held back divestitur divestitur
plan current compani ep guidanc exclud one-tim special bonu million non-senior
execut employe still target organ growth year includ benefit
price remain pre-tax synergi around million synergi expect
complet bulk synergi integr back offic system remain fx
expect neutral earn model oper margin record
aid divestitur improv result increment cost save synergi
project tax rate gross free cash flow estim per share
respect assum net incom million depreci amort million million
exclud intang amort around million alreadi deduct adjust net
incom figur capit spend million dividend million still project
million free cash flow
ep estim revenu billion oper incom
ep aid lower tax rate compani could begin see benefit
northwel partnership northwel hospit group account surgic procedur new york
deal give hub long island provid central steril process
northwel hospit partner could add million annual revenu well help
drive addit outsourc activ build finish outfit current
note earli sign potenti outsourc opportun oper margin model
bp revenu remain million cost synergi synergi anticip
long-term target mid-single-digit organ growth double-digit ep growth note
tax rate could low rang provid detail confer call
share trade forward ep estim project
year growth rate rate hold due valuat remain posit fundament
includ satisfactori hospit spend benefit acquir synergi margin improv aid
recent divestitur sell ev-to-ebitda ratio project ebitda million
project ebitda million share trade price-to-earnings ratio base upon trail
report ep current
pleas see import disclosur end report
divis wellington shield co llc
plc
global hospit spend environ key variabl synergi deriv revenu
outsid subject compani increas geograph risk well vagari foreign currenc
fluctuat medic technolog compani product obsolesc and/or increas competit
relev risk regulatori issu continu import mani compani product process
subject fda approv and/or inspect
pleas see import disclosur end report
divis wellington shield co llc
plc -- earn model -- februari
march fiscal year-end
mm ex per share
good sold
good sold
pleas see import disclosur end report
